Alpelisib in combination with fulvestrant approved in the EU for the treatment of breast cancer

The combination has been approved for the treatment of postmenopausal women and men with hormone receptor positive, HER2- locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.